Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005144430 | Thyroid | HT | negative regulation of ubiquitin-protein transferase activity | 8/1272 | 19/18723 | 1.71e-05 | 4.11e-04 | 8 |
GO:190466629 | Thyroid | HT | regulation of ubiquitin protein ligase activity | 8/1272 | 23/18723 | 8.66e-05 | 1.48e-03 | 8 |
GO:005143827 | Thyroid | HT | regulation of ubiquitin-protein transferase activity | 11/1272 | 53/18723 | 7.35e-04 | 8.21e-03 | 11 |
GO:0002181113 | Thyroid | PTC | cytoplasmic translation | 121/5968 | 148/18723 | 4.32e-36 | 4.54e-33 | 121 |
GO:1903320113 | Thyroid | PTC | regulation of protein modification by small protein conjugation or removal | 148/5968 | 242/18723 | 4.49e-21 | 8.10e-19 | 148 |
GO:0031396113 | Thyroid | PTC | regulation of protein ubiquitination | 128/5968 | 210/18723 | 3.06e-18 | 3.27e-16 | 128 |
GO:0051348113 | Thyroid | PTC | negative regulation of transferase activity | 137/5968 | 268/18723 | 3.78e-11 | 1.36e-09 | 137 |
GO:0072331113 | Thyroid | PTC | signal transduction by p53 class mediator | 92/5968 | 163/18723 | 7.29e-11 | 2.54e-09 | 92 |
GO:0031397113 | Thyroid | PTC | negative regulation of protein ubiquitination | 55/5968 | 83/18723 | 1.26e-10 | 4.28e-09 | 55 |
GO:1903321113 | Thyroid | PTC | negative regulation of protein modification by small protein conjugation or removal | 59/5968 | 95/18723 | 1.26e-09 | 3.63e-08 | 59 |
GO:1901796113 | Thyroid | PTC | regulation of signal transduction by p53 class mediator | 58/5968 | 93/18723 | 1.38e-09 | 3.95e-08 | 58 |
GO:0051444113 | Thyroid | PTC | negative regulation of ubiquitin-protein transferase activity | 17/5968 | 19/18723 | 2.98e-07 | 5.09e-06 | 17 |
GO:0051438111 | Thyroid | PTC | regulation of ubiquitin-protein transferase activity | 34/5968 | 53/18723 | 1.36e-06 | 1.95e-05 | 34 |
GO:1904667113 | Thyroid | PTC | negative regulation of ubiquitin protein ligase activity | 11/5968 | 12/18723 | 2.91e-05 | 2.82e-04 | 11 |
GO:1901798113 | Thyroid | PTC | positive regulation of signal transduction by p53 class mediator | 18/5968 | 25/18723 | 4.48e-05 | 4.05e-04 | 18 |
GO:1904666113 | Thyroid | PTC | regulation of ubiquitin protein ligase activity | 16/5968 | 23/18723 | 2.31e-04 | 1.67e-03 | 16 |
GO:0002181210 | Thyroid | goiters | cytoplasmic translation | 73/497 | 148/18723 | 1.65e-75 | 6.83e-72 | 73 |
GO:0031396210 | Thyroid | goiters | regulation of protein ubiquitination | 21/497 | 210/18723 | 2.06e-07 | 1.58e-05 | 21 |
GO:0072331210 | Thyroid | goiters | signal transduction by p53 class mediator | 18/497 | 163/18723 | 3.52e-07 | 2.47e-05 | 18 |
GO:1903320210 | Thyroid | goiters | regulation of protein modification by small protein conjugation or removal | 22/497 | 242/18723 | 5.56e-07 | 3.60e-05 | 22 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPS20 | SNV | Missense_Mutation | | c.40N>A | p.Glu14Lys | p.E14K | P60866 | protein_coding | tolerated(0.08) | benign(0.101) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPS20 | SNV | Missense_Mutation | | c.235C>T | p.Arg79Cys | p.R79C | P60866 | protein_coding | deleterious(0.04) | benign(0.168) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
RPS20 | SNV | Missense_Mutation | | c.254N>G | p.His85Arg | p.H85R | P60866 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
RPS20 | SNV | Missense_Mutation | novel | c.325G>A | p.Gly109Arg | p.G109R | P60866 | protein_coding | deleterious(0.01) | probably_damaging(0.958) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPS20 | SNV | Missense_Mutation | rs371598524 | c.403N>A | p.Glu135Lys | p.E135K | P60866 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.905) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
RPS20 | SNV | Missense_Mutation | | c.340G>A | p.Glu114Lys | p.E114K | P60866 | protein_coding | tolerated(0.08) | benign(0.185) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
RPS20 | SNV | Missense_Mutation | | c.197G>T | p.Arg66Ile | p.R66I | P60866 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
RPS20 | SNV | Missense_Mutation | novel | c.304A>G | p.Thr102Ala | p.T102A | P60866 | protein_coding | deleterious(0.04) | possibly_damaging(0.852) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
RPS20 | SNV | Missense_Mutation | novel | c.190N>G | p.Thr64Ala | p.T64A | P60866 | protein_coding | deleterious(0.02) | possibly_damaging(0.896) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPS20 | SNV | Missense_Mutation | | c.232N>A | p.Asp78Asn | p.D78N | P60866 | protein_coding | deleterious(0.02) | probably_damaging(0.984) | TCGA-49-AARN-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |